OKYO Pharma (OKYO) Equity Average (2022 - 2025)

OKYO Pharma (OKYO) has 4 years of Equity Average data on file, last reported at -$75.4 million in Q1 2025.

• Equity Average for Q1 2025 came in at -$75.4 million, down 216.41% year-over-year; the trailing twelve-month figure through Mar 2025 was -$75.4 million (down 216.41% YoY), and the FY2025 annual result was -$5.7 million, down 44.07% from the prior year.
• Equity Average held at -$75.4 million in Q1 2025 per OKYO's latest filing, from -$75.5 million in the prior quarter.
• Over five years, Equity Average peaked at $66.7 million in Q3 2023 and troughed at -$75.5 million in Q3 2024.
• A 4-year average of -$2.5 million and a median of $2.3 million in 2022 frame the typical range for Equity Average.
• The sharpest annual moves came in 2024 and 2025: Equity Average jumped 14383.49% in 2024, then tumbled 216.41% in 2025.
• A 4-year view of Equity Average shows it stood at $4.1 million in 2022, then soared by 1512.87% to $66.7 million in 2023, then slumped by 213.31% to -$75.5 million in 2024, then advanced by 0.22% to -$75.4 million in 2025.
• Business Quant data shows OKYO's Equity Average at -$75.4 million in Q1 2025, -$75.5 million in Q3 2024, and $64.8 million in Q1 2024.